

Boris Y Alekseev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4022884/publications.pdf>

Version: 2024-02-01

153
papers

13,499
citations

109321

35
h-index

23533

111
g-index

155
all docs

155
docs citations

155
times ranked

11429
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127. | 27.0 | 2,319 |
| 2 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115. | 27.0 | 1,824 |
| 3 | Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360. | 27.0 | 1,588 |
| 4 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300. | 27.0 | 956 |
| 5 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415. | 13.7 | 778 |
| 6 | ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2974-2986. | 1.6 | 643 |
| 7 | Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1235-1246. | 27.0 | 621 |
| 8 | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 686-700. | 10.7 | 496 |
| 9 | Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799. | 1.6 | 388 |
| 10 | Mitochondrial dysfunction and oxidative stress in aging and cancer. <i>Oncotarget</i> , 2016, 7, 44879-44905. | 1.8 | 381 |
| 11 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1132-1142. | 27.0 | 341 |
| 12 | Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 760-768. | 2.6 | 297 |
| 13 | Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 975-986. | 10.7 | 296 |
| 14 | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741. | 30.7 | 282 |
| 15 | Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. <i>New England Journal of Medicine</i> , 2020, 383, 1040-1049. | 27.0 | 225 |
| 16 | IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578. | 1.6 | 164 |
| 17 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277. | 13.7 | 153 |
| 18 | Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1616-1622. | 1.6 | 111 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Important molecular genetic markers of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 53959-53983. | 1.8 | 91 |
| 20 | Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307. | 1.6 | 75 |
| 21 | Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275. | 7.1 | 75 |
| 22 | Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1532-1542. | 10.7 | 65 |
| 23 | RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon β -2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1378-1384. | 1.2 | 64 |
| 24 | The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBP β rather than Enterotoxigenic <i>Bacteroides fragilis</i> Infection. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-11. | 4.0 | 63 |
| 25 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120. | 10.7 | 61 |
| 26 | MiRImpact, a new bioinformatic method using complete microRNA expression profiles to assess their overall influence on the activity of intracellular molecular pathways. <i>Cell Cycle</i> , 2016, 15, 689-698. | 2.6 | 58 |
| 27 | Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. <i>European Urology</i> , 2020, 77, 494-500. | 1.9 | 54 |
| 28 | Epigenetic Alterations of Chromosome 3 Revealed by NotI-Microarrays in Clear Cell Renal Cell Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-9. | 1.9 | 53 |
| 29 | Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. <i>BMC Genomics</i> , 2016, 17, 1011. | 2.8 | 50 |
| 30 | HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer. <i>BMC Genomics</i> , 2018, 19, 113. | 2.8 | 45 |
| 31 | Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. <i>Oncotarget</i> , 2014, 5, 9022-9032. | 1.8 | 43 |
| 32 | Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis. <i>Disease Markers</i> , 2015, 2015, 1-13. | 1.3 | 41 |
| 33 | 5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 | 2.6 | 39 |
| 34 | Downregulation of OGDHL expression is associated with promoter hypermethylation in colorectal cancer. <i>Molecular Biology</i> , 2015, 49, 608-617. | 1.3 | 37 |
| 35 | Molecular markers of paragangliomas/pheochromocytomas. <i>Oncotarget</i> , 2017, 8, 25756-25782. | 1.8 | 36 |
| 36 | Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells. <i>BMC Genetics</i> , 2016, 17, 156. | 2.7 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 161, 108-111. | 0.8 | 33 |
| 38 | Analysis of Plasma microRNA Associated with Hemolysis. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 748-750. | 0.8 | 32 |
| 39 | Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). <i>Annals of Oncology</i> , 2016, 27, 441-448. | 1.2 | 31 |
| 40 | MicroRNA hsa-miR-4674 in Hemolysis-Free Blood Plasma Is Associated with Distant Metastases of Prostatic Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 161, 112-115. | 0.8 | 30 |
| 41 | Exome analysis of carotid body tumor. <i>BMC Medical Genomics</i> , 2018, 11, 17. | 1.5 | 26 |
| 42 | A multinational phase II trial of bevacizumab with low-dose interferon- β 2a as first-line treatment of metastatic renal cell carcinoma: BEVLIN. <i>Annals of Oncology</i> , 2013, 24, 2396-2402. | 1.2 | 25 |
| 43 | Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. <i>European Journal of Cancer</i> , 2021, 154, 138-146. | 2.8 | 24 |
| 44 | Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 162, 379-382. | 0.8 | 23 |
| 45 | Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780. | 10.7 | 23 |
| 46 | Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 730. | 2.3 | 21 |
| 47 | Suppression of ITGB4 Gene Expression in PC-3 Cells with Short Interfering RNA Induces Changes in the Expression of β 2-Integrins Associated with RGD-Receptors. <i>Bulletin of Experimental Biology and Medicine</i> , 2015, 159, 541-545. | 0.8 | 19 |
| 48 | A systematic experimental evaluation of microRNA markers of human bladder cancer. <i>Frontiers in Genetics</i> , 2013, 4, 247. | 2.3 | 18 |
| 49 | Overexpression of microRNAs miR-9, -98, and -199 Correlates with the Downregulation of HK2 Expression in Colorectal Cancer. <i>Molecular Biology</i> , 2018, 52, 190-199. | 1.3 | 17 |
| 50 | Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234. | 5.4 | 17 |
| 51 | Upregulation of NETO2 gene in colorectal cancer. <i>BMC Genetics</i> , 2017, 18, 117. | 2.7 | 16 |
| 52 | Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer. <i>Journal of Bioinformatics and Computational Biology</i> , 2019, 17, 1950003. | 0.8 | 16 |
| 53 | Profile of microRNA in Blood Plasma of Healthy Humans. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 632-634. | 0.8 | 15 |
| 54 | Mutational load in carotid body tumor. <i>BMC Medical Genomics</i> , 2019, 12, 39. | 1.5 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Aberrant methylation of p16, HIC1, N33, and GSTP1 in tumor epithelium and tumor-associated cells in prostate cancer. <i>Molecular Biology</i> , 2007, 41, 70-76. | 1.3 | 11 |
| 56 | Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma. <i>Biochimie</i> , 2019, 157, 26-37. | 2.6 | 11 |
| 57 | Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 274-282. | 3.9 | 11 |
| 58 | Effects of <i>Abies sibirica</i> terpenes on cancer- and aging-associated pathways in human cells. <i>Oncotarget</i> , 2016, 7, 83744-83754. | 1.8 | 10 |
| 59 | Molecular genetic mechanisms of drug resistance in prostate cancer. <i>Molecular Biology</i> , 2015, 49, 638-648. | 1.3 | 9 |
| 60 | Expression of Stroma Components in the Lymph Nodes Affected by Prostate Cancer Metastases. <i>Molecular Biology</i> , 2018, 52, 701-706. | 1.3 | 9 |
| 61 | Plasma Level of hsa-miR-619-5p microRNA Is Associated with Prostatic Cancer Dissemination beyond the Capsule. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 163, 475-477. | 0.8 | 8 |
| 62 | Role of IGFBP6 Protein in the Regulation of Epithelial-Mesenchymal Transition Genes. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 650-654. | 0.8 | 8 |
| 63 | Transcription Factor SAP30 Is Involved in the Activation of NETO2 Gene Expression in Clear Cell Renal Cell Carcinoma. <i>Molecular Biology</i> , 2018, 52, 385-392. | 1.3 | 8 |
| 64 | Changes in the Metastatic Properties of MDA-MB-231 Cells after IGFBP6 Gene Knockdown Is Associated with Increased Expression of miRNA Genes Controlling INSR, IGF1R, and CCND1 Genes. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 166, 641-645. | 0.8 | 8 |
| 65 | Own Experience in Treatment of Patients with Penile Cancer Using Photodynamic Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-4. | 1.9 | 7 |
| 66 | In Vitro Model for Studying of the Role of IGFBP6 Gene in Breast Cancer Metastasizing. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 688-692. | 0.8 | 7 |
| 67 | Impact TMPRSS2-ERG Molecular Subtype on Prostate Cancer Recurrence. <i>Life</i> , 2021, 11, 588. | 2.4 | 7 |
| 68 | Application of loop-mediated isothermal amplification of DNA for diagnosis of prostate cancer micrometastases in the lymph nodes. <i>Onkourologiya</i> , 2017, 13, 63-66. | 0.3 | 7 |
| 69 | Loop-mediated isothermal amplification: an effective method for express-diagnostics of cancer. <i>Onkourologiya</i> , 2018, 14, 88-99. | 0.3 | 7 |
| 70 | Biomarkers of prostate cancer sensitivity to the Sendai virus. <i>Molecular Biology</i> , 2017, 51, 80-88. | 1.3 | 6 |
| 71 | Suppression of NROB2 gene in Clear Cell Renal Cell Carcinoma Is Associated with Hypermethylation of Its Promoter. <i>Molecular Biology</i> , 2018, 52, 414-418. | 1.3 | 5 |
| 72 | RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4518-4518. | 1.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer. <i>Current Genomics</i> , 2017, 18, 236-243. | 1.6 | 5 |
| 74 | Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis. <i>Biochemistry (Moscow)</i> , 2018, 83, 930-943. | 1.5 | 4 |
| 75 | Novel potential causative genes in carotid paragangliomas. <i>BMC Medical Genetics</i> , 2019, 20, 48. | 2.1 | 4 |
| 76 | Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5003-5003. | 1.6 | 4 |
| 77 | APHIG: a new multiparameter index for prostate cancer. <i>Onkourologiya</i> , 2016, 12, 94-103. | 0.3 | 4 |
| 78 | Surgical treatment of the stricture of the lower third of ureter after radiation therapy of pelvic organs. <i>Onkourologiya</i> , 2016, 12, 68-73. | 0.3 | 4 |
| 79 | Salvage lymphadenectomy in patients with lymphogenic prostate cancer progression after radical treatment: results of a multicenter study. <i>Onkourologiya</i> , 2016, 12, 70-80. | 0.3 | 4 |
| 80 | Targeted therapy in patients with poor-prognosis renal cell carcinoma. <i>Onkourologiya</i> , 2017, 13, 49-55. | 0.3 | 4 |
| 81 | Immunosuppressive peculiarities of stromal cells of various kidney tumor types. <i>Onkourologiya</i> , 2020, 16, 29-35. | 0.3 | 4 |
| 82 | MP28-10 PANEL OF 6 MICRORNAS FOR MINIMALLY INVASIVE DIAGNOSIS OF PROSTATE CANCER. <i>Journal of Urology</i> , 2017, 197, . | 0.4 | 3 |
| 83 | Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 166, 656-660. | 0.8 | 3 |
| 84 | The role of microRNA in the diagnosis of prostate cancer. <i>Onkourologiya</i> , 2021, 16, 172-180. | 0.3 | 3 |
| 85 | Surgical treatment of patients with high-risk prostate cancer: long-term outcomes and prognostic factors. <i>Onkourologiya</i> , 2021, 16, 99-111. | 0.3 | 3 |
| 86 | A system of a unified approach to interpreting prostate magnetic resonance imaging according to the PI-RADSV2 guidelines. <i>Onkourologiya</i> , 2016, 12, 81-89. | 0.3 | 3 |
| 87 | Potentialities of MicroRNA Diagnosis in Patients with Bladder Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 164, 106-108. | 0.8 | 2 |
| 88 | The effect of ELOVL6 fatty acid elongase inhibition on the expression of genes associated with the metastasis of breast cancer. <i>Russian Chemical Bulletin</i> , 2018, 67, 2307-2315. | 1.5 | 2 |
| 89 | The R.E.N.A.L. nephrometry score in radiologists' practice. <i>Onkourologiya</i> , 2021, 16, 17-31. | 0.3 | 2 |
| 90 | An original surgical method for the formation of fascial duplication in the elimination of damage to the anterior rectal wall during prostatectomy. <i>Onkourologiya</i> , 2021, 17, 54-61. | 0.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Comparing the efficacy of laparoscopic and open radical prostatectomy: analysis of treatment outcomes in patients with prostate cancer treated in three federal centers. <i>Onkourologiya</i> , 2021, 17, 45-53. | 0.3 | 2 |
| 92 | A phase II study of ^{99m} Tc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 94-94. | 1.6 | 2 |
| 93 | LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA3-LBA3. | 1.6 | 2 |
| 94 | Germline nonsense-mutations of the SMARCB1 gene in Russian patients with rhabdoid renal tumors. <i>Onkourologiya</i> , 2017, 13, 14-19. | 0.3 | 2 |
| 95 | Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma. <i>Onkourologiya</i> , 2018, 14, 68-78. | 0.3 | 2 |
| 96 | The role of molecular genetic alterations in sensitivity of the adjuvant intravesical therapy for non-muscle invasive bladder cancer. <i>Onkourologiya</i> , 2019, 14, 124-138. | 0.3 | 2 |
| 97 | Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer. <i>Onkourologiya</i> , 2016, 12, 109-110. | 0.3 | 2 |
| 98 | Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment. <i>Onkourologiya</i> , 2016, 12, 64-73. | 0.3 | 2 |
| 99 | Role of tumor-associated macrophages in renal cell carcinoma pathogenesis. <i>Onkourologiya</i> , 2017, 13, 20-26. | 0.3 | 2 |
| 100 | Prostate cancer brachytherapy. Experience of the branches of the National Medical Research Center of Radiology. <i>Onkourologiya</i> , 2018, 14, 94-99. | 0.3 | 2 |
| 101 | The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. <i>Prostate</i> , 2022, 82, 1237-1247. | 2.3 | 2 |
| 102 | 1258 ROLE OF A EXTENDED LYMPH NODE DISSECTION DURING RADICAL NEPHRECTOMY. <i>Journal of Urology</i> , 2011, 185, . | 0.4 | 1 |
| 103 | MP22-18 IDENTIFICATION OF NOVEL GENE EXPRESSION MARKERS FOR BLADDER CANCER DIAGNOSTICS. <i>Journal of Urology</i> , 2014, 191, . | 0.4 | 1 |
| 104 | Prediction of the Aggressive Status of Prostate Cancer on the Basis of Preoperative Data. <i>Journal of Communications Technology and Electronics</i> , 2017, 62, 1448-1455. | 0.5 | 1 |
| 105 | New Fluorescent Reporter Systems for Evaluation of the Expression of E- and N-Cadherins. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 165, 88-93. | 0.8 | 1 |
| 106 | Efficacy and safety of lenvatinib and everolimus combination in patients with metastatic renal cell carcinoma progression following targeted antiangiogenic therapy: secondary analysis of data obtained in the Russian multicenter observational study. <i>Onkourologiya</i> , 2021, 17, 31-44. | 0.3 | 1 |
| 107 | A phase 2 study of ^{99m} Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to histopathology: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16003-e16003. | 1.6 | 1 |
| 108 | NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. <i>Onkourologiya</i> , 2018, 14, 68-77. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Second line chemotherapy in patients with castration-refractory prostate cancer. From clinical studies to practice. <i>Onkourologiya</i> , 2019, 15, 84-91. | 0.3 | 1 |
| 110 | Basic characteristics and features of the molecular genetic test systems designed for non-invasive diagnostics and prognosis of prostate cancer and bladder cancer. <i>Onkourologiya</i> , 2020, 15, 18-29. | 0.3 | 1 |
| 111 | The validation of threshold decision rules and calculator for APhiG algorithm for clarification of prostate cancer staging before treatment. <i>Onkourologiya</i> , 2020, 16, 43-53. | 0.3 | 1 |
| 112 | Evaluation of the efficacy and safety of cabazitaxel in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have previously received docetaxel chemotherapy in daily clinical practice. Results of a Russian multicenter prospective study. <i>Onkourologiya</i> , 2020, 16, 66-77. | 0.3 | 1 |
| 113 | New treatment options for advanced urothelial cancer: a combination of atezolizumab with chemotherapy. <i>Onkourologiya</i> , 2020, 16, 104-117. | 0.3 | 1 |
| 114 | Genetic characteristics of the non-clear cell renal cancer. <i>Onkourologiya</i> , 2016, 12, 14-21. | 0.3 | 1 |
| 115 | The efficacy and safety of vinflunine in second-line therapy of patients with disseminated transitional cell carcinoma of the urinary tract in clinical practice. <i>Onkourologiya</i> , 2016, 12, 74-81. | 0.3 | 1 |
| 116 | Second-line hormonal therapy with the enzalutamid in patients with castrate-resistant prostate cancer. <i>Onkourologiya</i> , 2016, 12, 87-95. | 0.3 | 1 |
| 117 | Vinflunine as second-line therapy for advanced urothelial carcinoma: Russian observational study. <i>Onkourologiya</i> , 2017, 13, 110-118. | 0.3 | 1 |
| 118 | Multilocular cystic renal neoplasm of low malignant potential: experience of N.N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology. <i>Onkourologiya</i> , 2017, 13, 34-38. | 0.3 | 1 |
| 119 | Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer. <i>Onkourologiya</i> , 2018, 13, 85-90. | 0.3 | 1 |
| 120 | Expression of platelet-derived growth factor alpha and beta genes PDGFRA and PDGFRB associated with biochemical recurrence of prostate cancer after radical prostatectomy. <i>Onkourologiya</i> , 2018, 13, 45-50. | 0.3 | 1 |
| 121 | The problem of early continence recovery after radical prostatectomy. <i>Onkourologiya</i> , 2018, 13, 70-78. | 0.3 | 1 |
| 122 | Circulating microRNA expression in connection with prostate cancer lymphogenous metastasis. <i>Onkourologiya</i> , 2018, 14, 87-93. | 0.3 | 1 |
| 123 | CURRENTLY AVAILABLE TREATMENT OPTIONS FOR METASTATIC RENAL CELL CARCINOMA. <i>Onkourologiya</i> , 2018, 14, 25-36. | 0.3 | 1 |
| 124 | NEOADJUVANT AND ADJUVANT CHEMOHORMONAL THERAPY IN PATIENTS WITH HIGH-RISK AND VERY HIGH-RISK PROSTATE CANCER: OUR EXPERIENCE. <i>Onkourologiya</i> , 2018, 14, 58-67. | 0.3 | 1 |
| 125 | Surgical technique stabilization of urethrovesical anastomosis in order to improve the results of early recovery of urine retention after retropubic prostatectomy. <i>Onkourologiya</i> , 2019, 14, 68-78. | 0.3 | 1 |
| 126 | PI-RADS v2.1: moving towards clarity (comments on the updated version). <i>Onkourologiya</i> , 2020, 16, 15-28. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Current opportunities of therapy for patients with non-metastatic castration-resistant prostate cancer. <i>Onkourologiya</i> , 2020, 16, 190-197. | 0.3 | 1 |
| 128 | An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. <i>Onkourologiya</i> , 2020, 16, 90-101. | 0.3 | 1 |
| 129 | Experience of using 1 st line combination immunotherapy in patients with metastatic renal cell carcinoma. <i>Onkourologiya</i> , 2021, 17, 47-63. | 0.3 | 1 |
| 130 | Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 162, 375-378. | 0.8 | 0 |
| 131 | Features of Construction of the Fluorescent Microscope for the Study of Epithelial-Mesenchymal Transition of Cells in Vitro. <i>Optics and Spectroscopy (English Translation of Optika I Spektroskopiya)</i> , 2018, 125, 137-143. | 0.6 | 0 |
| 132 | Diferelin® as an effective chemical castration agent for patients with prostate cancer. <i>Onkourologiya</i> , 2021, 16, 191-196. | 0.3 | 0 |
| 133 | Large bladder leiomyoma: a case report. <i>Onkourologiya</i> , 2021, 16, 215-219. | 0.3 | 0 |
| 134 | Clinical significance of mutations in DNA repair genes in patients with metastatic prostate cancer. <i>Onkourologiya</i> , 2021, 17, 82-88. | 0.3 | 0 |
| 135 | <i>FGFR3</i> , <i>TERT</i> , <i>CD53</i> mutations and the <i>FGFR3</i> gene expression in bladder cancer as prognostic markers. <i>Onkourologiya</i> , 2021, 17, 89-100. | 0.3 | 0 |
| 136 | Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists. <i>Onkourologiya</i> , 2021, 17, 83-92. | 0.3 | 0 |
| 137 | 323: Diagnostic Efficacy of Sentinel Lymph Nodes Detection during Extended Pelvic Lymphadenectomy in Prostate Cancer Patients. <i>Journal of Urology</i> , 2007, 177, 109-109. | 0.4 | 0 |
| 138 | RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 560-560. | 1.6 | 0 |
| 139 | Optimization of sequential targeted therapy. <i>Onkourologiya</i> , 2016, 12, 22-29. | 0.3 | 0 |
| 140 | RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 611-611. | 1.6 | 0 |
| 141 | Prospects of 2nd line chemotherapy personalization in patients with metastatic castration-resistant prostate cancer. <i>Onkourologiya</i> , 2016, 12, 104-109. | 0.3 | 0 |
| 142 | Use of sunitinib in patients with metastatic kidney cancer in real clinical practice. <i>Onkourologiya</i> , 2016, 12, 14-20. | 0.3 | 0 |
| 143 | Comparative analysis of the PCA3 gene expression in sediments and exosomes isolated from urine. <i>Onkourologiya</i> , 2017, 13, 54-60. | 0.3 | 0 |
| 144 | Neoadjuvant chemohormonal therapy and radical prostatectomy in a patient with lymphogenic metastatic prostate cancer. <i>Onkourologiya</i> , 2017, 13, 148-154. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: a phase II, multicenter, single-arm, open-label study. <i>Onkourologiya</i> , 2018, 14, 117-125. | 0.3 | 0 |
| 146 | Comparison of the EORTC and CUETO prognostic models in non-muscle-invasive bladder cancer. <i>Onkourologiya</i> , 2018, 14, 162-170. | 0.3 | 0 |
| 147 | Radium chloride [223Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations. <i>Onkourologiya</i> , 2020, 16, 114-123. | 0.3 | 0 |
| 148 | Comparative clinical and economic analysis of using cabozantinib as second-line therapy for adult patients with advanced renal cell carcinoma. <i>Onkourologiya</i> , 2020, 16, 52-64. | 0.3 | 0 |
| 149 | The prevalence of prostate cancer from 2005 to 2010 in terms of patient survival. <i>Onkourologiya</i> , 2020, 16, 126-134. | 0.3 | 0 |
| 150 | Combination of nivolumab and ipilimumab in the treatment of disseminated renal cell carcinoma. Realities and prospects. <i>Onkourologiya</i> , 2020, 16, 38-52. | 0.3 | 0 |
| 151 | Long-term treatment outcomes of patients with non-clear cell renal cell carcinoma. <i>Onkourologiya</i> , 2021, 17, 39-46. | 0.3 | 0 |
| 152 | Current capabilities in treatment of non-metastatic castration-resistant prostate cancer: effectiveness, safety, and quality of life of patients taking darolutamide. <i>Onkourologiya</i> , 2021, 17, 78-84. | 0.3 | 0 |
| 153 | Morphological prerequisites for the formation of fascial duplication in the elimination of damage to the anterior rectal wall during prostatectomy. <i>Innovative Medicine of Kuban</i> , 2021, , 18-25. | 0.2 | 0 |